Sickle Cell Disease is Not a Joke
This weekend’s Saturday Night Live skit about the recent historic approvals of potentially curative gene therapies for sickle cell disease is... Continue Reading
SCDAA Statement About Gene Therapy Approval
On Dec. 8, 2023, the Food and Drug Administration (FDA) approved two cell-based gene therapies for sickle cell disease (SCD), Casgevy... Continue Reading
Gene Therapy is Approved!
We are very excited to share that today, Dec. 8, the Food and Drug Administration approved two gene therapies to treat... Continue Reading
Sickle Cell Awareness Month 2023 Events
All across the country, our member organizations are hosting exciting events for Sickle Cell Awareness Month this September. Check out the... Continue Reading
SCDAA Teams with MedicAlert Foundation
Sickle Cell Disease Association of America Teams with MedicAlert Foundation to Improve Emergency Outcomes During Sickle Cell Crises Nonprofits partner to... Continue Reading
Afimmune joins the SCD C.A.R.E.S. Consortium
Dublin, Ireland, 19 June 2023: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced it has been invited to... Continue Reading
SCDAA Announces FY24 Legislative Priorities
Did you know that the federal government is poised to make some of the biggest decisions in sickle cell history right... Continue Reading
SCDAA names new board members
The Sickle Cell Disease Association of America, a national nonprofit membership organization that advocates for people affected by sickle cell, named... Continue Reading
SCDAA to promote clinical trials
The Sickle Cell Disease Association of America, a national nonprofit membership organization that advocates for people affected by sickle cell, formed... Continue Reading
Urge Officials to Cosponsor the SCD Comprehensive Care Act
Dear Sickle Cell Community, Over the past several months, SCDAA has been working with congressional sickle cell disease (SCD) champions and... Continue Reading